EU revokes Tecfidera patent

The European Patent Office revoked EU Patent No. EP2137537 from Biogen Inc. (NASDAQ:BIIB), company spokesperson Lindsey Smith told BioCentury. The patent, which expires in 2028, covers treatment of multiple sclerosis with 480 mg of Tecfidera dimethyl fumarate.

Joel Sendek, CFO of Forward Pharma A/S (NASDAQ:FWP), told BioCentury that Forward was one of several parties that challenged the '537 patent in Europe. Sendek said Forward holds a European patent covering the 480 mg dose of dimethyl fumarate, adding that "right now, we have an issued patent in Europe and Biogen doesn't." ...